Fore Capital LLC Acquires New Stake in Grifols, S.A. (NASDAQ:GRFS)

Fore Capital LLC bought a new stake in Grifols, S.A. (NASDAQ:GRFS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 130,000 shares of the biotechnology company's stock, valued at approximately $967,000.

A number of other large investors have also recently bought and sold shares of the company. R Squared Ltd purchased a new position in shares of Grifols during the 4th quarter valued at about $28,000. GAMMA Investing LLC grew its holdings in Grifols by 44.5% during the fourth quarter. GAMMA Investing LLC now owns 4,959 shares of the biotechnology company's stock worth $37,000 after acquiring an additional 1,527 shares during the period. Blue Trust Inc. raised its position in Grifols by 254.0% during the fourth quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company's stock valued at $52,000 after acquiring an additional 4,970 shares in the last quarter. Raymond James Financial Inc. acquired a new position in Grifols in the fourth quarter valued at approximately $91,000. Finally, HighTower Advisors LLC boosted its position in Grifols by 12.5% in the 3rd quarter. HighTower Advisors LLC now owns 13,930 shares of the biotechnology company's stock worth $123,000 after purchasing an additional 1,546 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley initiated coverage on shares of Grifols in a report on Wednesday, February 12th. They set an "overweight" rating for the company.

Remove Ads

Grifols Price Performance

Shares of NASDAQ:GRFS traded up $0.12 during trading on Monday, reaching $8.10. 390,072 shares of the company's stock traded hands, compared to its average volume of 1,265,167. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a fifty-two week low of $5.79 and a fifty-two week high of $9.96. The company has a 50-day simple moving average of $7.50 and a 200-day simple moving average of $8.13. The firm has a market cap of $5.57 billion, a PE ratio of 6.92 and a beta of 0.35.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.